BRCA1 Germline Mutations and Polymorphisms in a Clinic-Based Series of Ovarian Cancer Cases: A Gynecologic Oncology Group Study

By Smith S.A.   Richards W.E.   Caito K.   Hanjani P.   Markman M.   DeGeest K.   Gallion H.H.  

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 586-592

Elsevier

Access to resources Recommend Favorite

A Phase II Study of Intraperitoneal Cisplatin and Thiotepa in Residual Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Feun L.G.   Blessing J.A.   Major F.J.   DiSaia P.J.   Alvarez R.D.   Berek J.S.  

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 410-415

Elsevier

Access to resources Recommend Favorite

Dactinomycin in the Treatment of Recurrent or Persistent Endometrial Carcinoma: A Phase II Study of the Gynecologic Oncology Group

By Moore D.H.   Blessing J.A.   Dunton C.   Buller R.E.   Reid G.C.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 473-475

Elsevier

Access to resources Recommend Favorite

A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study

By Rose P.G.   Brunetto V.L.   VanLe L.   Bell J.   Walker J.L.   Lee R.B.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 212-216

Elsevier

Access to resources Recommend Favorite

Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study

By Covens A.   Brunetto V.L.   Markman M.   Orr J.W.   Lentz S.S.   Benda J.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 470-474

Elsevier

Access to resources Recommend Favorite